Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, November 9, 2017
[ Thu, Nov 09th 2017
] - WOPRAI
Wed, November 8, 2017
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
[ Wed, Nov 08th 2017
] - WOPRAI
David Buck Maintained (SUPN) at Strong Buy with Decreased Target to $50 on, Nov 8th, 2017
David Buck of B. Riley Securities, Maintained "Supernus Pharmaceuticals, Inc." (SUPN) at Strong Buy with Decreased Target from $53 to $50 on, Nov 8th, 2017.
David has made no other calls on SUPN in the last 4 months.
There are 2 other peers that have a rating on SUPN. Out of the 2 peers that are also analyzing SUPN, all agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- David Amsellem of "Piper Sandler" Downgraded from Buy to Hold on, Monday, July 17th, 2017
- Ken Trbovich of "Janney Montgomery Scott" Initiated at Hold and Held Target at $47 on, Friday, July 14th, 2017
